Despite its advantages, Kadcyla is not without limitations. Its use is restricted to HER2-positive cancers, which limits its applicability to other cancer types. Additionally, the development of resistance to Kadcyla can occur, necessitating the need for alternative treatments. The cost of Kadcyla can also be a barrier for some patients, as it is a relatively expensive therapy.
